Profectus HIV MAG pDNA vaccine

**Profectus HIV MAG pDNA vaccine** is an investigational multiantigen plasmid-DNA therapeutic and preventive HIV-1 vaccine developed by Profectus BioSciences. The product is an admixture of two DNA expression vectors that encode HIV-1 clade B antigens: Gag/Pol, Nef/Tat/Vif, and Env gp160. Following intramuscular administration with electroporation, host cells express these antigens to elicit HIV-specific cellular immune responses, including T-cell responses. It was studied in Phase 1 trials in people with HIV-1 receiving antiretroviral therapy and in healthy HIV-uninfected adults, often with separately co-administered IL-12 plasmid-DNA adjuvant and, in some studies, a subsequent recombinant VSV-Gag boost. ([cdek.pharmacy.purdue.edu](https://cdek.pharmacy.purdue.edu/trial/NCT01266616/))

Other names

HIV-MAG DNA vaccineHIV-MAG pDNA vaccineHIV-1 multiantigen pDNA vaccineHIV1 multiantigen pDNA vaccineHIV 1 multiantigen pDNA vaccineMAg-pDNA vaccine